1. Home
  2. |Insights
  3. |ARIAS 2017 Spring Conference

ARIAS 2017 Spring Conference

Event | 05.03.17 - 05.05.17, 12:00 AM UTC - 12:00 AM UTC

Address

Ritz-Carlton Naples, FL
280 Vanderbilt Beach Rd, Naples, FL 34108

The risk landscape is ever evolving as emerging risks continue to develop and change at a rapid pace. For the re/insurance industry, the march of progress and modern technology has heightened the awareness of risk, bringing with it a sense of uncertainty as well as unexpected opportunities. What are these new and unforeseen risks, and what opportunities do they present to re/insurers? Connect with other participants in small, in depth, roundtable discussions moderated by industry experts. Seize the opportunity to discuss new trends, exchange best practices, and build on existing knowledge. Each roundtable will focus on an emerging risk topic, including: Autonomous Vehicles, Big Data, Blockchain Technology, Cybersecurity, Drones, ERM, GMOs, Nanotechnology, Opioid Crisis, and Talcum Powder.


Round 1: 3:35 p.m. – 4:25 p.m.
Round 2: 4:35 p.m. – 5:25 p.m.


Roundtable Leaders:

David McLauchlin, The McLauchlin Law Group
Charles T. Morris, Hanover Stone Solutions, LLC
Joseph Sano, Prince Lobel Tye LLP
Laura A. Foggan, Crowell & Moring LLP
Dale Crawford, ARIAS•U.S. Arbitrator
Tom Cunningham, Sidley Austin LLP
Elizabeth Kniffen, Zelle Hofmann Voelbel & Mason LLP
Royce Cohen, Tressler LLP
Tom Bernier, Goldberg Segalla LLP
Ryan Russell, San Francisco Reinsurance Company
Timothy Curley, San Francisco Reinsurance Company
Kelsey Brunette, Munich Re America
Kevin J. Tierney, Disability RMS
Jay Kenigsberg, Rivkin Radler

Participants

Insights

Event | 12.04.25

ACI 30th Annual Conference on Drug & Medical Device Litigation

Dan Campbell with Speak on the panel "Mastering MDL Case Management: What Proposed Rule 16.1 Really Means for Consolidated Litigation."
Rule 16.1 attempts to guide early case management in MDLs, impacting litigation pace and costs. Permissive language like “should” instead of “must”, could lead to inconsistent applications. This panel will explore the rule’s anticipated impact and implications for procedures.